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High blood pressure (BP) has been ranked as the most important risk factor worldwide regarding attributable deaths. Dietary habits are major deter-
minants of BP.Among them, frequent intake of low-fat dairy productsmay protect against hypertension. Our aimwas to assess the relationship between
low-fat dairy product intake and BP levels and their changes after 12-month follow-up in a cohort of asymptomatic older persons at high cardiovascular
risk recruited into a large-scale trial assessing the effects of Mediterranean diets on cardiovascular outcomes. Data from 2290 participants, including
1845with hypertension, were available for analyses. Dairy products were not a specific part of the intervention; thus, data were analysed as an observa-
tional cohort. Dietary information was collected with validated semi-quantitative FFQ and trained personnel measured BP. To assess BP changes, we
undertook cross-sectional analyses at baseline and at the end of follow-up and longitudinal analyses. A statistically significant inverse association
between low-fat dairy product intake and systolic BP was observed for the 12-month longitudinal analysis. In the longitudinal analysis, the adjusted
systolic and diastolic BPwere significantly lower in the highest quintile of low-fat dairy product intake ( 2 4·2 (95%CI 2 6·9, 2 1·4) and 2 1·8 (95%
CI 2 3·2, 2 0·4) mmHg respectively), whereas the point estimates for the difference in diastolic BP indicated amodest non-significant inverse associ-
ation. Intake of low-fat dairy products was inversely associated with BP in an older population at high cardiovascular risk, suggesting a possible pro-
tective effect against hypertension.
Low-fat dairy products: Blood pressure: Dietary pattern: Cardiovascular risk: PREDIMED study
Worldwide, it has been estimated that there are one billion
hypertensive individuals(1) and that hypertension is the most
important attributable risk factor for death(2). Small population
reductions in blood pressure (BP) of 2–5mmHg are translated
into important reductions in mortality due to stroke and CHD
and in total mortality(3). For this reason, new approaches
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should be evaluated and implemented to reduce BP levels.
Although diet is acknowledged as a major determinant of BP,
the role of some foods is still controversial. One preventive strat-
egy that has been shown to be beneficial is the DASHdiet(4). The
results from the DASH trial suggest that a dietary pattern rich in
fruits and vegetables, poor in SFA and with increased intake of
low-fat dairy products can be an effective means to prevent the
development of hypertension. The DASH trial tested the effects
on BP of a complex dietary pattern, not of particular foods
(i.e. low-fat dairy products); thus, there is no clinical trial evi-
dence to support a specific BP-lowering effect of low-fat dairy
products.Nonetheless, the results of a large prospective observa-
tional cohort, the SUNStudy(5), suggested that the intake of low-
fat dairy products was associated with a reduction of incident
hypertension. Indeed, participants in the highest quintile of
low-fat dairy intake halved their risk of developing hyperten-
sion. In the CARDIA study, also a prospective study, the authors
found an inverse association between total dairy product intake
and 10-year cumulative incidence of hypertension among over-
weight people(6). These resultswere partially confirmed by those
of the National Heart, Lung, and Blood Institute Family Heart
Study(7), in which an inverse association between consumption
of dairy products and prevalence of hypertension was observed.
However, this was a cross-sectional study that did not assess the
specific relationship of low-fat dairy products to BP.
From a biological point of view, protection against hyper-
tension by low-fat dairy products has been attributed to their
nutrient composition. Dairy products are good sources of K,
Mg, Ca, peptides with an inhibitory effect on angiotensin-I-
converting enzyme activity and opioid-like peptides(8,9,10).
On the other hand, whole-fat dairy products are rich in SFA,
and high-SFA diets impair endothelial function(11). All these
mechanisms add biological plausibility to the hypothesis of
a specific protection against hypertension provided by low-
fat dairy products. There is scarce epidemiological evidence
of a specific effect on BP of these foods in persons at elevated
cardiovascular risk with a high frequency of treated hyperten-
sion. The aim of the present study was to assess the relation-
ship between low-fat dairy product intake and BP in an
observational follow-up study conducted in a large population
at high cardiovascular risk participating in the PREDIMED
study, a trial to test the effects of the Mediterranean diet on
cardiovascular outcomes(12).
Methods
Study population
The present study has been conducted within the frame of the
PREDIMED trial. The design of the PREDIMED trial has
been reported in detail elsewhere(12). Briefly, the PREDIMED
trial is a large, parallel-group, multicentre, randomized and con-
trolled 4-year clinical trial that aims to assess the effects of a
Mediterranean-type diet on CVD and in which participants are
assigned to one of three different dietary patterns (low-fat diet;
Mediterranean diet supplemented with nuts; Mediterranean
diet supplemented with olive oil)(12). The study population
is composed of men aged between 55 and 80 years and
women aged between 60 and 80 years with no previously
documented CVD but at high cardiovascular risk. Inclusion
criteria were either diabetes mellitus type 2 or at least three
of the following risk factors: current smoking; hypertension;
hyperlipidaemia; HDL-cholesterol ,1·034mmol/L; over-
weight/obesity; family history of premature CHD.
In the present analysis, data from this trial were analysed as
an observational cohort study because the evaluated exposure
(intake of low-fat dairy products) was not a part of the
intervention.
In the present analyseswe included data from the first enrolled
participants in the PREDIMED trial, in which the retention rate
during the first year was greater than 90%. These earlier partici-
pants were not significantly different regarding socio-demo-
graphic characteristics and risk factors from those subsequently
recruited for the trial. Data from 2392 participants who com-
pleted questionnaires at baseline and after 12 months of
follow-up were available. We excluded sixteen participants
who had missing values for baseline BP and twenty-seven
with missing BP data at 12 months. Participants reporting
extreme total energy intakes with values outside pre-specified
limits (2093 to 14650 kJ/d in women and 3349 to 16743 kJ/d
in men)(13) were excluded from the analysis. The effective
sample size for statistical analyses was 2290. All participants
provided informed consent and the protocol was approved by
the institutional review boards of all participating centres
according to the Declaration of Helsinki(14).
Dietary assessment
The dietary habits of participants, both at baseline and after
follow-up for 12 months, were assessed using a semi-quanti-
tative 137-item FFQ previously validated in Spain(15). The
questionnaire was based on the typical portion sizes that
were multiplied by the consumption frequency for each
food. Nutrient composition was estimated from Spanish food
composition tables(16,17).
Information about dairy products was assessed in fifteen
items of the semi-quantitative FFQ (whole-fat milk, partially
skimmed milk, skimmed milk, condensed milk, whipped
cream, yoghurt, skimmed yoghurt, milkshake, ricotta cheese
or junket, petit Suisse cheese, spreadable cheese wedges,
cottage cheese, other cheese, custard, and ice cream). Partially
skimmed milk, skimmed milk, skimmed yoghurt and cottage
cheese were considered low-fat dairy products.
Blood pressure measurements
At baseline and after 12 months follow-up, trained personnel
measured BP in triplicate with a validated semi-automatic
oscillometer (Omron HEM-705CP; Hoofddorp, The Nether-
lands) while the participant was in a seated position after
5min rest. The mean of the three systolic BP (SBP) and dias-
tolic BP (DBP) measurements was calculated(18,19). Arm cir-
cumference determined the cuff size and BP was measured
in the forearm at heart level.
Assessment of other covariates
Smoking status was categorized into never, current or past
smoking according to self-reports. Participants were considered
as diabetic, hyperlipidaemic or hypertensive if they had a pre-
vious diagnosis of these conditions and/or they were treated
with anti-diabetic, cholesterol-lowering or anti-hypertensive
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agents, respectively. Information about treatment with non-ster-
oidal anti-inflammatory drugs, drugs that may decrease or
increase serum Ca levels or K supplements was also collected.
The highest achieved educational level was recorded. Physi-
cal activity was determined with the validated Spanish version
of the Minnesota questionnaire(20,21). The mean year meta-
bolic rate was derived from the information on sixty-seven
different activities and their energy expenditure and expressed
in kJ/d. Trained personnel measured height and weight with
calibrated scales and wall-mounted stadiometers, respectively.
BMI was calculated as the weight divided by the square of the
height (kg/m2).
At each visit, information on medication intake of each par-
ticipant was collected for oral anti-diabetic agents and insulin
treatment, cholesterol-lowering drugs (statins, fibrates, resins
or others) and anti-hypertensive agents (angiotensin-convert-
ing enzyme inhibitors, inhibitors of the angiotensin II AT1
receptors, other anti-hypertensive drugs (anti-adrenergics
with peripheral action, arteriolar vasodilators (including Ca
entry blockers), diuretics and nitrates)). Information about
treatment with non-steroidal anti-inflammatory drugs, drugs
that may decrease or increase serum Ca levels or K sup-
plements was also collected.
Statistical analysis
Food and nutrient intakes were adjusted for total energy intake
using the residual method(13). Missing values in potential
confounding factors were entered as an additional category
in the multivariable models.
Participants were divided into five groups according to
quintiles of consumption of low-fat dairy or whole-fat dairy
products. Hereby, we avoided making specific assumptions
about the shape of the dose–response relationship and thus
minimized the influence of outliers(13). First, we compared
the crude means for SBP and DBP across quintiles of dairy
product consumption (separately for low-fat and whole-fat
items). Afterwards, multivariable linear regression models
were fit to control for potential confounders, such as the pre-
sence of diabetes mellitus, mean physical activity during the
previous year, anti-hypertensive treatment, treatment with
non-steroidal anti-inflammatory drugs or drugs that may
modify serum Ca, alcohol consumption, use of K supplements,
total energy intake, intake of Na (including Na from salt used
for seasoning meals), of SFA, MUFA and fibre, consumption
of fruits and vegetables and the non-dairy intake of K, Ca, Mg
and total protein. Fish and whole grain intakes were also con-
sidered as potentially confounding factors in ancillary ana-
lyses. Multivariable linear regression models were fitted
considering current BMI as a potential confounder. However,
current BMI may also be considered as an intermediate vari-
able in the association between low-fat dairy consumption
and BP and, therefore, we constructed models both adjusted
for BMI and not adjusted for BMI. Although smoking status
and hyperlipidaemia have not been established as risk factors
for hypertension, they were also controlled for as indicators of
lifestyle-related factors.
For each exposure (low-fat and whole-fat dairy products)
we fitted five multivariable linear regression models: (1) a
baseline cross-sectional analysis (exposure: baseline dairy
product consumption; outcome: baseline BP); (2) a 12-month
cross-sectional analysis (exposure: dairy product consumption
after 12 months; outcome: BP after 12 months); (3) a conven-
tional longitudinal analysis (exposure: baseline dairy product
consumption; outcome: BP after 12 months); (4) a longitudinal
analysis with BP changes as outcome (exposure: baseline
dairy product consumption; outcome: BP changes during
follow-up); (5) a dynamic longitudinal analysis (exposure:
changes in dairy product consumption; outcome: changes in
BP). In the models in which the outcome was 12 months BP,
BP changes and/or when the exposure was 12 months dairy pro-
duct consumption, we additionally adjusted for the intervention
group. Our sample size provided a statistical power greater than
90% todetect between-quintile (first v.fifth) differences of 3 and
2mmHg in SBP and DBP changes, respectively, assuming stan-
dard deviation values of 13mmHg for SBP and 7 for DBP. For
linear trend tests, each quintile of dairy consumption was
assigned its median value and the resulting variable was con-
sidered as quantitative in the multivariable analyses. We tested
interactions between low-fat or whole-fat dairy products con-
sumption and obesity, diabetes mellitus, hypertension and treat-
ment with anti-hypertensive agents in the conventional
longitudinal analyses. CI at 95% were calculated in every
model including all the data.
All significance levels were calculated two-sided and
all analyses were performed with SPSS version 13.0
(SPSS Inc., Chicago, IL, USA).
Results
The characteristics of participants are presented in Table 1
according to their baseline consumption of low-fat dairy pro-
ducts. Women and never-smokers consumed more and past
smokers consumed less low-fat dairy products. Participants
with a higher consumption of low-fat dairy products also
had a lower intake of total energy, alcohol, Ca and protein
from non-low-fat dairy sources. Low-fat and whole-fat dairy
consumption were inversely correlated (r 20·43; P,0·001).
Tables 2 and 3 show the BP levels and their changes during
follow-up according to low-fat and whole-fat dairy products
consumption, respectively.
Regarding low-fat dairy consumption, we found inverse
linear trends for SBP that were statistically significant in
the cross-sectional analysis after the 12 months follow-up.
The test of linear trend in the cross-sectional analyses at
baseline was also marginally significant and the CI did not
include the null value for the comparison of SBP levels
between the upper and lower quintiles of low-fat dairy pro-
ducts in both cross-sectional analyses. More importantly, in
the conventional longitudinal analysis with SBP levels after
12 months, we found an inverse linear trend and the CI for
the comparison of SBP across extreme quintiles of low-fat
dairy product consumption did not include the null value.
When we did not adjust the multivariable regression model
for current BMI, the comparison between extreme quintiles
and the linear trend did not appreciably change (data not
shown). All point estimates for the comparison between
extreme quintiles showed a negative sign, indicating an
inverse association between low-fat dairy product consump-
tion and SBP. Only one of the adjusted analyses for DBP
suggested an inverse association for the consumption of
low-fat dairy products (P for trend 0·01 for the cross-sectional
Low-fat dairy products and blood pressure 61
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Table 1. Baseline characteristics of 2290 participants in the PREDIMED trial across quintiles of low-fat dairy consumption*
(Means and standard deviations or percentages)
Quintiles of low-fat dairy consumption at baseline
Q1 Q2 Q3 Q4 Q5
Sample size (n). . . 458 458 458 458 458
Mean SD Mean SD Mean SD Mean SD Mean SD P for trend
Low-fat dairy products (g/d) 3·1 17·1 141·1 53·3 236·7 26·8 406·1 80·1 631·6 139·4
Total dairy products (g/d) 262·1 216·0 238·0 121·4 295·4 67·6 460·9 119·9 664·9 146·1
Whole-fat dairy products (g/d) 261·1 218·3 99·0 123·3 60·6 63·9 56·8 84·2 34·9 55·9
Age (years)† 67·2 6·4 66·7 6·1 67·0 6·1 67·7 5·9 68·1 5·9 0·001
Sex (% females) 37·3 44·3 55·4 64·9 73·8 ,0·001
BMI (kg/m2)‡ 29·6 3·5 29·5 3·5 29·9 3·6 29·7 3·7 30·0 4·3 0·04
Educational level (%)§
. secondary 25·8 26·4 26·4 21·8 21·0 0·03
Physical activity (kJ/d) 1102 1018 1109 1015 1073 957 1018 929 1049 956 0·17
Smokers (%)
Past 32·3 28·4 26·6 19·0 17·0 ,0·001
Current 20·1 15·9 14·4 12·0 10·0 ,0·001
Hyperlipidaemia (%)k 63·1 66·4 68·1 65·7 71·6 0·02
Diabetes mellitus (%) 48·5 47·8 52·6 48·9 52·4 0·23
Hypertension (%) 83·2 79·9 81·9 81·9 76·0 0·03
Use of NSAID (%) 20·3 23·6 22·7 21·8 27·5 0·04
Use of ACE inhibitors or ARA (%) 46·3 46·3 45·0 41·7 40·4 0·03
Use of other anti-hypertensive drugs (%) 38·2 40·4 46·3 43·7 43·2 0·07
Use of drugs that may rise calcaemia (%){ 4·4 5·2 5·9 5·7 7·2 0·07
Use of drugs that may lower calcaemia (%)** 3·3 4·4 5·0 5·7 5·7 0·05
K supplements (%) 0·2 0·7 0·7 0·4 0·7 0·54
Total energy intake (kJ/d) 10 208 2297 9460 2351 9230 2335 9314 2059 9335 2100 ,0·001
Na (mg/d) 2366 696 2374 582 2355 542 2349 611 2333 571 0·30
K from other sources than dairy (mg/d) 4026 805 3881 741 3863 756 3755 721 3685 802 ,0·001
Ca from other sources than dairy products (mg/d) 837 300 640 201 585 171 575 197 523 173 ,0·001
Mg from other sources than dairy products (mg/d) 352 71 342 66 337 65 324 63 316 6689 ,0·001
Alcohol (g/d) 21·5 55·4 34·1 128·5 19·7 48·3 11·3 31·5 8·5 27·1 ,0·001
Fat (% total energy intake) 40·5 6·7 40·2 6·6 39·3 6·9 39·6 6·4 38·5 7·0 ,0·001
SFA (% total energy intake) 10·7 2·3 9·9 2·2 9·7 2·1 9·9 2·2 9·7 2·2 ,0·001
MUFA (% total energy intake) 20·2 4·5 20·2 4·4 19·9 4·5 20·1 4·3 19·3 4·7 0·003
Protein from other sources than dairy (g/d) 87·0 13·5 82·2 12·7 81·7 12·7 78·3 12·9 74·4 13·0 ,0·001
Fibre (g/d) 24·0 7·9 24·8 7·2 24·9 7·0 24·8 7·0 24·7 7·4 0·26
Vegetables (g/d) 308·7 151·5 317·9 129·9 321·1 138·1 322·3 130·0 325·4 159·7 0·07
Fruits (g/d) 350·1 216·6 362·0 207·8 363·9 205·1 366·5 182·3 371·7 195·9 0·11
NSAID, non-steroid anti-inflammatory drugs; ACE, angiotensin-converting enzyme; ARA, angiotensin II receptor antagonists.
* For details of subjects and procedures, see Methods.
Missing values: † 7; ‡ 41; § 64; k 1.
{Use of Ca supplements and/or vitamin D.
** Use of bisphosphonates and/or calcitonin.
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Table 2. Blood pressure (BP) levels and BP changes across quintiles of low-fat dairy consumption*
(Means and 95 % CI)
Systolic BP Diastolic BP
Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q5
Sample size. . . 458 458 458 458 458
P for
trend 458 458 458 458 458
P for
trend
Baseline, cross-sectional
Mean BP 152·7 150·0 150·3 150·9 148·8 0·01 84·9 83·5 83·6 84·2 82·4 0·003
95 % CI 150·8, 154·6 147·5, 152·5 147·8, 152·8 148·4, 153·4 146·2, 151·3 83·8, 85·9 82·2, 84·9 82·2, 84·5 82·8, 85·5 81·0, 83·8
Adjusted
model†
0 22·7 22·9 21·9 23·7 0·05 0 21·4 21·4 20·4 21·7 0·13
95 % CI (ref) 25·2, 20·1 25·5, 20·3 24·5, 0·8 26·5, 20·9 (ref) 22·7, 20·1 22·8, 20·06 21·8, 1·0 23·2, 20·3
12 month cross-sectional
Mean BP 151·5 148·7 149·4 148·2 147·6 0·002 83·9 83·1 82·0 82·1 82·3 0·01
95 % CI 149·5, 153·4 146·2, 151·1 146·9, 151·8 145·8, 150·7 145·1, 150·0 82·9, 84·9 81·8, 84·5 80·7, 83·3 80·8, 83·4 81·0, 83·6
Adjusted
model‡
0 23·2 22·2 23·6 24·5 0·001 0 21·0 21·1 22·2 21·4 0·01
95 % CI (ref) 25·7, 20·8 24·7, 0·3 26·1, 21·1 27·1, 22·0 (ref) 22·3, 0·2 22·4, 0·2 23·5, 21·0 22·7, 20·1
Longitudinal, baseline
exposure 12 month BP
Mean BP 150·9 148·6 149·2 149·3 147·3 0·02 83·4 82·4 82·8 83·1 81·7 0·04
95 % CI 149·0, 152·8 146·1, 151·0 146·7, 151·6 146·9, 151·8 144·9, 149·8 82·5, 84·4 81·0, 83·7 81·4, 84·1 81·8, 84·4 80·4, 83·0
Adjusted
model‡
0 22·8 22·5 22·2 24·2 0·01 0 21·5 21·1 20·5 21·8 0·09
95 % CI (ref) 25·3, 20·3 25·1, 0·03 24·8, 0·4 26·9, 21·4 (ref) 22·8, 20·2 22·4, 0·3 21·9, 0·8 23·2, 20·4
ref, Reference.
* For details of subjects and procedures, see Methods.
† Adjusted for age, sex, centre, BMI, physical activity, treatment with non-steroid anti-inflammatory drugs (yes/no), treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists (yes/no), treatment with
other anti-hypertensive drugs (yes/no), smoking status (never, current, past smoker), hyperlipidaemia (yes/no), diabetes mellitus (yes/no), total energy intake, intake of alcohol and Na, treatment with drugs that may increase calcae-
mia (yes/no), treatment with drugs that may decrease calcaemia (yes/no), treatment with K supplements (yes/no), dietary intake of K, Ca, Mg and protein from sources other than low-fat dairy products, saturated fatty acids, MUFA,
fibre, fruit and vegetable. All quantitative variables have been introduced in quintiles.
‡ With additional adjustment for intervention group.
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Table 3. Blood pressure (BP) levels and BP changes across quintiles of whole-fat dairy consumption*
(Means and 95 % CI)
Systolic BP Diastolic BP
Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q5
Sample size. . . 458 458 458 458 458 P for trend 458 458 458 458 458 P for trend
Baseline, cross-sectional
Mean BP 149·0 149·1 151·7 150·5 152·4 0·02 82·0 83·4 85·2 83·7 84·4 0·09
95 % CI 147·1, 150·8 146·5, 151·6 149·2, 154·2 148·0, 153·0 149·8, 154·9 81·0, 83·0 82·0, 84·7 83·8, 86·5 82·3, 85·0 83·0, 85·8
Adjusted model† 0 20·6 1·6 0·6 2·4 0·19 0 0·3 2·0 0·9 2·3 0·08
95 % CI (ref) 23·1, 1·9 21·1, 4·4 22·4, 3·5 21·0, 5·9 (ref) 21·0, 1·6 0·5, 3·4 20·6, 2·5 0·6, 4·1
12 month cross-sectional
Mean BP 147·2 148·5 149·8 150·3 149·5 0·28 81·5 82·4 83·9 83·1 82·5 0·87
95 % CI 145·5, 148·9 146·0, 150·9 147·3, 152·2 147·9, 152·8 147·0, 151·9 80·6, 82·4 81·1, 83·7 82·5, 85·2 81·8, 84·4 81·2, 83·9
Adjusted model‡ 0 0·9 2·3 2·4 0·7 0·74 0 1·0 2·3 1·7 1·6 0·35
95 % CI (ref) 21·5, 3·4 20·1, 4·7 20·1, 4·9 21·9, 3·3 (ref) 20·2, 2·3 1·0, 3·5 0·4, 3·0 0·3, 2·9
Longitudinal, baseline exposure 12 months BP
Mean BP 148·2 147·6 149·4 148·5 151·6 0·002 81·9 82·5 83·3 82·7 83·1 0·34
95 % CI 146·5, 149·9 145·1, 150·0 146·9, 151·8 146·1, 151·0 149·1, 154·1 81·0, 82·8 81·2, 83·8 82·0, 84·6 81·4, 84·0 81·7, 84·4
Adjusted model‡ 0 20·8 0·2 21·2 0·0 0·84 0 20·3 0·2 20·2 0·3 0·61
95 % CI (ref) 23·3, 1·7 22·5, 2·9 24·1, 1·7 23·4, 3·3 (ref) 21·6, 0·9 21·3, 1·5 21·6, 1·3 21·4, 2·0
ref, Reference.
* For details of subjects and procedures, see Methods.
† Adjusted for age, sex, centre, BMI, physical activity, treatment with non-steroid anti-inflammatory drugs (yes/no), treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists (yes/no), treatment with
other anti-hypertensive drugs (yes/no), smoking status (never, current, past smoker), hyperlipidaemia (yes/no), diabetes mellitus (yes/no), total energy intake, intake of alcohol and Na, treatment with drugs that may increase calcae-
mia (yes/no), treatment with drugs that may decrease calcaemia (yes/no), treatment with K supplements (yes/no), dietary intake of K, Ca, Mg and protein from sources other than whole-fat dairy products, saturated fatty acids from
sources other than dairy products, MUFA, fibre, fruit and vegetable. All quantitative variables have been introduced in quintiles.
‡ With additional adjustment for intervention group.
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analysis after 12 months follow-up). However, the point esti-
mates for the difference in DBP between the upper and lower
quintiles of low-fat dairy product intake always had a negative
sign and were statistically significant, suggesting a modest
non-significant inverse association. Neither the comparisons
across extreme quintiles nor the linear trend tests in the longi-
tudinal analysis with change in BP as outcome or in the
dynamic longitudinal analysis were statistically significant
(data not shown).
No significant trends were observed in the analyses using
whole-fat dairy product consumption as exposure. It is note-
worthy that, contrary to what we observed for low-fat dairy
products, the point estimates for the adjusted comparisons
between extreme quintiles of whole-fat dairy product con-
sumption had always but once a positive sign, suggesting a
modest non-significant positive association. In the longitudinal
analysis with change in BP as outcome and in the dynamic
longitudinal analysis no comparison among extreme quintiles
was statistically significant (data not shown).
When we additionally adjusted for fish or whole grain intake,
the results did not substantially change (data not shown).
We found no interaction between low-fat and whole-fat
dairy product consumption and obesity, diabetes mellitus,
hypertension or treatment with anti-hypertensive agents (data
not shown).
Discussion
The results of the present study suggest a beneficial effect of
low-fat dairy product consumption on BP.
To our knowledge, the present study is the first large pro-
spective cohort observing an inverse association between
low-fat dairy products and BP in an older population at high
cardiovascular risk during a 12-month follow-up. The large
sample size and the thorough information collected allowed
us to comprehensively adjust for potential confounding,
including both dietary and non-dietary confounders. Nonethe-
less, the current study has some limitations. First, we acknow-
ledge that our participants are not a representative sample of
the general population in the statistical sense. This is true
for most samples used in randomized trials and epidemiologi-
cal cohorts; however, this does not preclude performing scien-
tific inferences(22). In addition to this, the observed magnitude
of the BP effect associated with low-fat dairy product intake
was not very large, i.e. in the longitudinal analysis there
were reductions of up to 4mmHg in SBP. Nevertheless,
reductions of 2–5mmHg in average BP levels at the popu-
lation level may reduce all-cause mortality, fatal CHD and
fatal stroke by 7%, 9% and 14%, respectively(3). This is
important from a public health perspective. Another potential
limitation is that residual confounding might explain part of
the observed associations because dietary variables are
imperfectly measured by the instruments used in nutritional
epidemiology(23). Furthermore, it could be argued that the
observed lower BP levels among consumers of low-fat dairy
products may not be attributable to a specific effect of these
foods but to other aspects of an overall healthier lifestyle
that are not captured by the information collected in Table 1.
This is unlikely, however, because subjects in the top quintile
of low-fat dairy product intake had a higher BMI, a lower
educational level and alcohol intake and were less physically
active and less likely to be past smokers than those in the
lowest quintile. More importantly, if the parameters that we
estimated for the association between dairy product consump-
tion and BP had been substantially reduced when adjusting for
potential confounders, we could conclude that the observed
effect might still be attributable to unmeasured confounding.
This was not the case, since multivariate-adjusted estimates
taking into account potential lifestyle-related confounders
did not show a noticeable reduction in the magnitude of the
effect with regard to unadjusted estimates. Therefore, it is
unlikely that a large degree of residual confounding might
be responsible for the observed association. Moreover, some
of the observed associations were not linear. Indeed, a
linear, monotonically decreasing pattern would have strength-
ened the case for a causal relationship. We do not have a
definitive explanation for the non-linear shape, although
random error and non-differential misclassification of
exposure for intermediate quintiles may contribute to this
shape of the dose–response curve. Despite this, it is note-
worthy that most adjusted point estimates for the fifth quintile
showed the lowest value for BP when low-fat dairy products
were considered as the exposure.
Findings from other studies also support the results from
the present study. First, in some cohorts a beneficial effect
of total dairy consumption on BP was observed(6,24,25). In
the Coronary Artery Risk Development in Young Adults
cohort study(6), the 10-year cumulative incidence of elevated
BP was inversely associated with total dairy intake only
among overweight participants. In addition, the protective
effect of an increment of one daily eating occasion of a
reduced-fat dairy product was higher than the protective
effect of that of a serving of a high-fat dairy product.
These findings also suggested a specific protective effect of
low-fat dairy products and provided consistency for the pre-
sent results. However, after 15-years of follow-up in the same
cohort(26), only milk and dairy desserts, but not total dairy
products, were inversely related to elevated BP. In a cross-
sectional study conducted in Greece(25), an inverse associ-
ation between dairy product consumption and DBP was
also found; however, there was no significant association
for SBP.
Other studies have suggested a differential effect on BP of
low- v. whole-fat dairy consumption, with a beneficial effect
shown for low-fat products(5,7). In a Spanish cohort study
including middle-aged adults (the SUN Study)(5), an inverse
association between low-fat dairy products, but not whole-
fat dairy products, and the risk of hypertension was found.
Consistently, total dairy product intake and low-fat dairy
intake have been found to be negatively associated with the
risk of hypertension among middle-aged and older women
in a recent prospective cohort study(27). In another study con-
ducted in an elderly population(28), only total dairy product
intake was modestly associated with lower levels of DBP;
however, no statistical differences were found when separ-
ating low-fat dairy products from whole-fat dairy products.
The DASH trial(4) and others(29) have shown beneficial effects
on BP of dietary patterns including low-fat dairy products;
however, the intervention was not focused exclusively on
these foods. No other randomized trial has assessed the iso-
lated effect on BP of low-fat dairy products.
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The differential association between low-fat dairy product
consumption and whole-fat dairy product consumption and
BP found in the present cohort is consistent with the results
of other studies(5,7,27) and might be explained by the deleter-
ious effect of the SFA contained in whole-fat dairy products
on endothelial function(11).
Nonetheless, we found no statistically significant associations
when assessing howBP changedwith changes in the exposure to
low-fat dairy products, and this finding should temper our con-
clusions. However, point estimates for differences between
extreme quintiles were in the expected direction. The lack of
statistical significance for some analyses could be explained
by the advanced age of our participants and their high frequency
and long duration of hypertension, making it difficult to attain
substantial changes in BP with only a change in a single nutri-
tional exposure during a 12-month period.
In the CARDIA cohort study(6), there was a significant
interaction between a higher BMI and the consumption of
dairy products on the risk of high BP. Since participants of
the PREDIMED trial are at high cardiovascular risk, only
very few of them had a normal weight. Therefore, our statisti-
cal power to perform subgroup analyses regarding overweight
status was insufficient. However, we found no interaction
between low-fat or whole-fat dairy consumption and obesity
for the association with BP levels.
In conclusion, low-fat dairy products could play an impor-
tant role in the prevention of hypertension and may be helpful
in the control and reduction of BP levels. The current study
fills one gap in the available evidence about the effects of
dairy products in elderly high-risk populations, suggesting
that low-fat dairy products could also be potentially beneficial
in this group. To confirm our findings, large clinical trials
designed specifically to assess the role of low-fat dairy pro-
ducts on BP levels or on the incidence of hypertension
should be conducted.
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